MoldCo has reduced the price of its Starter Health Panel from $99 to $56, lowering the cost of blood-based mold illness screening for consumers without specialist access. The panel measures three biomarkers, TGF-beta1, MMP-9, and MSH, which researchers associate with immune-mediated responses to mold exposure. Testing is available at more than 2,000 LabCorp locations across the United States.
The panel is structured around the Shoemaker Protocol, a clinical framework developed to identify and treat what proponents call Chronic Inflammatory Response Syndrome (CIRS), a condition attributed to biotoxin exposure including mold. The protocol remains a subject of ongoing discussion within mainstream medicine, though its biomarker-based approach has a following among practitioners who specialize in environmental illness.
The pricing shift is notable given that mold-related illness is frequently underdiagnosed, in part because conventional screening tools are limited. Some estimates suggest that roughly 24% of the population carries genetic variants that may reduce the body's ability to clear biotoxins efficiently, making them more susceptible to prolonged symptoms after mold exposure. For individuals experiencing unexplained fatigue, cognitive difficulty, or respiratory issues in water-damaged environments, accessible biomarker testing represents one avenue for gathering objective data before pursuing clinical evaluation.